Allison Bratzel
Stock Analyst at Piper Sandler
(4.69)
# 155
Out of 5,129 analysts
57
Total ratings
71.11%
Success rate
19.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Neutral | $35 → $38 | $30.22 | +25.74% | 4 | Feb 6, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $77 → $87 | $84.35 | +3.14% | 4 | Feb 6, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $84 | $60.31 | +39.28% | 1 | Feb 6, 2026 | |
| INCY Incyte | Maintains: Overweight | $102 → $110 | $98.84 | +11.29% | 4 | Feb 6, 2026 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $6 → $4 | $1.55 | +158.06% | 2 | Feb 6, 2026 | |
| REPL Replimune Group | Maintains: Overweight | $13 → $14 | $7.76 | +80.41% | 3 | Feb 5, 2026 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $3 → $4 | $2.48 | +61.29% | 1 | Feb 5, 2026 | |
| IOBT IO Biotech | Downgrades: Neutral | $3 → $0.5 | $0.36 | +40.65% | 2 | Jan 26, 2026 | |
| TYRA Tyra Biosciences | Maintains: Overweight | $33 → $42 | $29.99 | +40.05% | 2 | Jan 23, 2026 | |
| MGTX MeiraGTx Holdings | Maintains: Overweight | $28 → $30 | $7.46 | +302.14% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $820 → $930 | $834.55 | +11.44% | 15 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $52 → $51 | $47.14 | +8.19% | 4 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $112 | $122.77 | -8.77% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $115 | $23.88 | +381.57% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $9.93 | +161.83% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $23 | $34.94 | -34.17% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $26.80 | -17.91% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $1.01 | +296.04% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $6.40 | +212.50% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $3.13 | +538.98% | 1 | Oct 13, 2023 |
Travere Therapeutics
Feb 6, 2026
Maintains: Neutral
Price Target: $35 → $38
Current: $30.22
Upside: +25.74%
Ionis Pharmaceuticals
Feb 6, 2026
Maintains: Overweight
Price Target: $77 → $87
Current: $84.35
Upside: +3.14%
BioMarin Pharmaceutical
Feb 6, 2026
Maintains: Overweight
Price Target: $122 → $84
Current: $60.31
Upside: +39.28%
Incyte
Feb 6, 2026
Maintains: Overweight
Price Target: $102 → $110
Current: $98.84
Upside: +11.29%
Akebia Therapeutics
Feb 6, 2026
Maintains: Overweight
Price Target: $6 → $4
Current: $1.55
Upside: +158.06%
Replimune Group
Feb 5, 2026
Maintains: Overweight
Price Target: $13 → $14
Current: $7.76
Upside: +80.41%
ALX Oncology Holdings
Feb 5, 2026
Maintains: Overweight
Price Target: $3 → $4
Current: $2.48
Upside: +61.29%
IO Biotech
Jan 26, 2026
Downgrades: Neutral
Price Target: $3 → $0.5
Current: $0.36
Upside: +40.65%
Tyra Biosciences
Jan 23, 2026
Maintains: Overweight
Price Target: $33 → $42
Current: $29.99
Upside: +40.05%
MeiraGTx Holdings
Nov 11, 2025
Maintains: Overweight
Price Target: $28 → $30
Current: $7.46
Upside: +302.14%
Nov 4, 2025
Maintains: Overweight
Price Target: $820 → $930
Current: $834.55
Upside: +11.44%
Sep 24, 2025
Maintains: Overweight
Price Target: $52 → $51
Current: $47.14
Upside: +8.19%
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $122.77
Upside: -8.77%
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $23.88
Upside: +381.57%
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $9.93
Upside: +161.83%
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $34.94
Upside: -34.17%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $26.80
Upside: -17.91%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $1.01
Upside: +296.04%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $6.40
Upside: +212.50%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $3.13
Upside: +538.98%